This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Epidemiology

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The incidence of status epilepticus is 20/100,000 for Caucasians in industrialised countries (1).

  • the incidence of SE has a bimodal distribution
    • the first peak seen during the first year of life while the second peak occuring after the age of 60 years
    • among adults, the highest risk of developing SE is seen in patients older than 60, with an incidence of 86 per 100,000 persons per year
    • among children, the highest incidence and prevalence of SE was observed in babies less than 12 months (1)

Status epilepticus occurs most frequently in patients without a prior diagnosis of epilepsy;

  • 5% of adults with epilepsy will experience at least one episode of status epilepticus
  • the common causes of status epilepticus in a patient with a prior diagnosis of epilepsy are:
    • drug withdrawal
    • intercurrent illness
    • metabolic disturbance
    • progression of the underlying disease

Mortality rates related to SE is around 7% in children while in adults it is around 28%. An increase in mortality is seen with age, duration of SE and the underlying cause (2).

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.